Human Vaccines & Immunotherapeutics
Volume 9, 2013 - Issue 6
Related Research Data
Clinical experience with respiratory syncytial virus vaccines.
Source:
Ovid Technologies (Wolters Kluwer Health)
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
Source:
Ovid Technologies (Wolters Kluwer Health)
New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV
Source:
MDPI AG
Implementation of Cocooning against Pertussis in a High-Risk Population
Source:
Oxford University Press (OUP)
Respiratory syncytial virus vaccine development.
Source:
Informa UK Limited
Comparisons between ethnic groups in hospitalizations for respiratory syncytial virus bronchiolitis in Israel.
Source:
Public Library of Science (PLoS)
Risk factors for severe respiratory syncytial virus lower respiratory tract infection.
Source:
Bentham Science Publishers Ltd.
Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines—Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High-Risk Elderly Individuals
Source:
Oxford University Press (OUP)
The burden of respiratory syncytial virus infection in young children.
Source:
Massachusetts Medical Society
Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008
Source:
Oxford University Press (OUP)
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
Source:
Elsevier BV
The Natural History of Respiratory Syncytial Virus in a Birth Cohort: The Influence of Age and Previous Infection on Reinfection and Disease
Source:
Oxford University Press (OUP)
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.
Source:
Oxford University Press (OUP)
Respiratory Syncytial Virus Hospitalizations Among American Indian and Alaska Native Infants and the General United States Infant Population
Source:
American Academy of Pediatrics (AAP)
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.
Source:
Springer Science and Business Media LLC
A multifaceted approach to RSV vaccination.
Source:
Informa UK Limited
Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
Source:
Bentham Science Publishers Ltd.
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
Source:
Ovid Technologies (Wolters Kluwer Health)
Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment
Source:
American Society for Microbiology
Immunity to and Frequency of Reinfection with Respiratory Syncytial Virus
Source:
Oxford University Press (OUP)
Respiratory virus prophylaxis in congenital heart disease.
Source:
Future Medicine Ltd
Improving rates of maternal immunization: Challenges and opportunities
Source:
Informa UK Limited
RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE
Source:
Oxford University Press (OUP)
Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention
Source:
Springer Nature
Prospects for defined epitope vaccines for respiratory syncytial virus
Source:
Future Medicine Ltd
Linking provided by
